Injectable Melanoma Therapy to Move into Phase 3

Share this content:

(ChemotherapyAdvisor) – Provectus Pharmaceuticals (Knoxville, TN) has received guidance from the U.S. Food and Drug Administration (FDA) to move forward with Phase 3 clinical trials for PV-10, an injectable formulation of Rose Bengal, which had previously shown an ability to destroy melanoma tumors with minimal damage to surrounding tissues. The news comes just 2 weeks after the company announced that they will be presenting final Phase 2 data on PV-10 at the upcoming 2nd European Post-ASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

In Phase 2 trials, patients were highly responsive to treatment with PV-10, with regression seen in 50% of all injected tumors. Approximately 50% of patients who experienced a local tumor response also experienced a response in a distant tumor that had not been injected. The distant response is very encouraging, as it demonstrates activation of systemic anti-tumor immunity.

According to Provectus Pharmaceuticals, Phase 2 trials for PV-10 demonstrated a mean Progression Free Survival (PFS) of 8.2 months for all subjects, while the overall response cohort had a significantly longer PFS estimated to be 11.7 months vs. 4.1 months for stable disease or progressive disease subjects; subjects with cutaneous or nodal disease achieved a mean PFS of 8.8 months vs. 6.2 months for subjects with visceral metastases.

“Provectus Pharmaceuticals is seeking consensus from FDA on a Phase 3 study design that will qualify for Special Protocol Assessment for PV-10 and support FDA approval,” the company wrote.

Press Release (Phase 3)

Press Release (Phase 2 Results)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs